First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

NCT07756281 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Pancreatic Acinar Carcinoma

Interventions

DRUG: SNV1521
DRUG: daraxonrasib

Sponsor

Synnovation Therapeutics, Inc.

Collaborators

[object Object]